Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.

[1]  A. Sood,et al.  The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. , 2022, Gynecologic oncology.

[2]  R. L. Hollis,et al.  Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial , 2022, The Lancet.

[3]  Y. Lee,et al.  Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan , 2020, Scientific Reports.

[4]  D. Gershenson,et al.  Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for the relative efficacy of tamoxifen and aromatase inhibitors. , 2020, Gynecologic oncology.

[5]  Kylie L. Gorringe,et al.  Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities , 2020, The Journal of pathology.

[6]  A. Tinker,et al.  Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes. , 2020, Gynecologic oncology.

[7]  D. Huntsman,et al.  Low-grade serous ovarian cancer: State of the science. , 2020, Gynecologic oncology.

[8]  A. Talhouk,et al.  Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. , 2020, Gynecologic oncology.

[9]  C. Genestie,et al.  Ovarian and peritoneal psammocarcinoma: Results of a multicenter study on 25 patients. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  A. deFazio,et al.  PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. , 2019, Gynecologic oncology.

[11]  A. Sood,et al.  The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. , 2019, Gynecologic oncology.

[12]  E. Martinelli,et al.  Hormone receptor expression profile of low-grade serous ovarian cancers. , 2017, Gynecologic oncology.

[13]  M. Birrer,et al.  Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer. , 2017, Obstetrics and gynecology.

[14]  D. Bodurka,et al.  Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. McKenney,et al.  Low-grade Serous Carcinoma of the Ovary: Clinicopathologic Analysis of 52 Invasive Cases and Identification of a Possible Noninvasive Intermediate Lesion , 2016, The American journal of surgical pathology.

[16]  I. Shih,et al.  Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? , 2016, Gynecologic oncology.

[17]  A. Reuss,et al.  Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. , 2016, Gynecologic oncology.

[18]  D. Bodurka,et al.  Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Kalloger,et al.  Stage II to IV Low-grade Serous Carcinoma of the Ovary Is Associated With a Poor Prognosis: A Clinicopathologic Study of 32 Patients From a Population-based Tumor Registry , 2013, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[20]  R. Bristow,et al.  Survival in Women With Grade 1 Serous Ovarian Carcinoma , 2013, Obstetrics and gynecology.

[21]  D. Bodurka,et al.  Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. , 2012, Gynecologic oncology.

[22]  R. Bristow,et al.  The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study. , 2012, Gynecologic oncology.

[23]  A. Sood,et al.  Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. , 2009, Gynecologic oncology.

[24]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[25]  A. Sood,et al.  Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary , 2006, Obstetrics and gynecology.

[26]  Z. Chaudry,et al.  Psammocarcinoma of the ovary: a case report and review of the literature , 2006, Gynecological Surgery.

[27]  M. Rettenmaier,et al.  Serous psammocarcinoma of the ovary: an unusual finding. , 2005, Gynecologic oncology.

[28]  Michael T Deavers,et al.  Grading Ovarian Serous Carcinoma Using a Two-Tier System , 2004, The American journal of surgical pathology.

[29]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[30]  C. Gilks,et al.  Serous psammocarcinoma of the ovary and peritoneum. , 1990, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[31]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .